Admin_Adham
Jump to Key Points Could a migraine preventive also move the needle on weight? A new long-term analysis of daily atogepant 60 mg set out to explore that question, and the results are worth a closer look for clinicians managing patients with both conditions.
1. Why Look at Weight in a Migraine Trial?
Obesity, overweight, and migraine have a bidirectional relationship: excess weight is associated with more frequent and severe attacks, while migraine itself can complicate weight management through reduced activity and disrupted routines. Given this connection, along with earlier signals that calcitonin gene-related peptide (CGRP) targeting therapies might influence appetite and metabolism, researchers conducted a post hoc analysis of a long-term atogepant extension study to examine weight outcomes. Findings were originally reported at the American Academy of Neurology 2026 Annual Meeting, and have since been published.
2. The Patients Behind the Data
The analysis included 279 adults with episodic or chronic migraine and a body mass index (BMI) of 25 or higher. Participants were predominantly women, and many carried multiple cardiovascular risk factors. The primary outcomes assessed were overall weight change and the proportion of patients achieving clinically meaningful weight loss at week 52.
3. Timing and Pattern of Weight Loss
Weight loss began early, with patients losing an average of about 2 lb within the first 4 weeks. The decline continued over the course of the year in a cyclical pattern of plateaus followed by renewed loss, a trajectory researchers described as typical for gradual weight loss. By week 52, approximately 30% of patients had lost at least 5% of baseline body weight, and about 13% had lost at least 10%.
- Atogepant 60 mg daily associated with gradual weight loss over 52 weeks.
- Weight loss began within 4 weeks; cyclical plateaus then renewed decline.
- ~30% lost ≥5% baseline weight; ~13% lost ≥10% by week 52.
- Nausea/constipation transient; weight loss not linked to GI adverse effects.
- Consider weight/CV risk as tiebreaker in migraine preventive selection.
4. Gastrointestinal Side Effects Not to Blame
The weight loss did not appear to be explained by GI side effects. Nausea and constipation were transient and did not correlate with the degree of weight change observed. Weight-related adverse events were uncommon and did not lead to treatment discontinuation. This dissociation points to a possible alternative mechanism, potentially involving CGRP pathway effects on appetite regulation and metabolism, rather than a drug-tolerability effect.
5. Clinical Application Today
Given the post hoc nature of this analysis, atogepant should not be prescribed for the goal of weight loss alone. It may, however, serve as a reasonable tiebreaker when choosing among migraine preventive therapies for a patient with excess weight or related cardiovascular risk factors. Improved migraine control itself may also help patients resume routines, such as physical activity and regular eating patterns, that support weight management independent of any direct drug effect.
Bottom Line
Daily atogepant 60 mg was associated with gradual, sustained weight loss in a meaningful subset of patients with migraine and elevated BMI, with about one third reaching a 5% loss and a smaller group reaching 10% by 1 year. The effect appears early, follows a gradual and cyclical course, and does not seem driven by tolerability issues. Current evidence supports considering weight as one factor among several when selecting atogepant, rather than treating it as an indication for weight loss on its own.
This article is based on a recent Medscape article titled Migraine Med Shows Weight-Loss Benefit and was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
